Catalog No.
DHJ24003
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8NBP7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LY-3015014, CAS: 1643672-70-1
Clone ID
Frovocimab
[PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know], PMID: 28709786
Quantitative characterization of the mechanism of action and impact of a 'proteolysis-permitting' anti-PCSK9 antibody, PMID: 27981884
Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody, PMID: 26392590
Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study, PMID: 26757788
Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients, PMID: 27822850
[PCSK-9 inhibitors, effects on LDL-C and future implications: What you should know]., PMID:28709786
Quantitative characterization of the mechanism of action and impact of a 'proteolysis-permitting' anti-PCSK9 antibody., PMID:27981884
Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients., PMID:27822850
Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study., PMID:26757788
Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody., PMID:26392590
For research use only. Not for human or drug use.
